<![CDATA[FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer]]>

RegulatoryGiredestrantPositive

AI Analysis

Summary

FDA granted priority review to giredestrant for ER+/HER2– early breast cancer following positive Phase 3 lidERA trial results showing improved invasive disease-free survival compared to endocrine therapy.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Priority Review granted

Importance:7/10

Sentiment:

0.80

FDAPriority ReviewBreast CancerPhase 3lidERA TrialER+ HER2-

Read the original article

Published by Cancer Network on June 3, 2026 3:30 PM

Read Original